Za a iya gwada gwaji na VAP Cholesterol don gano cututtukan ka?
Gwajin gwajin ta VAP, ko jarrabawar jarrabawar ta atomatik, yana da cikakken cikakken bayani akan gwajin cholesterol ko lipid panel. Ya ƙunshi ma'aunin da ke bin sababbin maganin maganin zazzaɓin cholesterol kuma zai iya ƙwarewa ta hanyar masu samarwa da ke kula da maganin babban cholesterol. Zai iya iya gano wasu mutane masu hadari ga cututtukan zuciya a baya a rayuwa.
An jarraba gwajin gwajin ta atomatik (VAP) ta masu bincike a Birmington, Alabama kuma sun gabatar da kasuwanci ta hanyar Atherotech, Inc. FDA ta amince da shi a shekarar 2007.
Ana gwada gwajin VAP tare da Furofidin Lipidin Cholesterol
Kwafin gwajin cholesterol na gargajiya yana aiki ne ta hanyar zub da jini a cikin wani mai tsadar sauri don rarraba lipids (fats). Wannan gwajin gwajin, wanda ake kira lipidro profile, ya bambanta nau'i uku na lipid : lipoproteins high-density, ko HDL; ƙananan lipoproteins, ko LDL; da kuma triglycerides, babban nau'i na mai a jikin.
Amma kusan kusan dukkanin mutane da suka kamu da ciwon zuciya, ka'idar lipid na yau da kullum ba ta nuna matsala ba. A cewar Atherotech, jarrabawar VAP za ta iya gane sau biyu a matsayin mutane da yawa da ke fuskantar hadarin zuciya, idan aka kwatanta da fasaha na al'ada.
Harshen cholesterol na gargajiya na gargajiya:
- LDL Levels
- Ƙididdigar HDL
- Matakan Triglyceride
A cikin gwaji na cholesterol, wadannan matakan ana lissafi ta amfani da takamammen tsari. Sabanin haka, sabon gwajin VAP zai iya auna wadannan matakan kai tsaye.
Ta yaya aikin gwajin VAP yake
Kamar labarun lipid, gwajin VAP yana aiki ne ta hanyar yin amfani da samfurin jini don raba lipids da nauyi. Amma jarrabawar VAP ta bada ƙarin bayyani fiye da gwaji na al'ada.
Alal misali, jarrabawar VAP ta raba LDL cholesterol ta girman girman dangi da kuma karya HDL cholesterol zuwa cikin takaddama. Binciken na yau da kullum ya nuna cewa wasu alamu na kamfanonin LDL masu girma zasu iya nuna haɗari mafi girma ga ci gaba da cututtukan zuciya. Bugu da ƙari, ƙaddarar ɗakunan HDL, HDL2, ana daukar su musamman mai kare zuciya.
Binciken na VAP yana ƙaddamar da wasu jinin jini cewa bayanin martaba na yanzu yana kasa kunne, kamar lipoprotein low-density (VLDL); matsakaicin matsanancin lipoprotein (IDL); da lipoprotein (a) [Lp (a)]. Masu bincike na Atherotech sun ce ana auna waɗannan nau'o'in nau'i na lipid da ƙananan raƙuman ruwa zasu iya bayyana ƙarin bayani game da hadarin ciwon zuciya na zuciya, wanda gwajin na gargajiya zai iya rasa.
Menene Sakamakon VAP
- Duka VLDL: Matakan VLDL da aka haɓaka sun dace da ƙari ciwon cututtukan zuciya da ciwon sukari.
- Jimlar Cholesterol Kudi: Jimlar HDL, LDL da VLDL matakan.
- Jimlar ba HDL: Jimlar kawai LDL da VLDL matakan; Matsayin da ya fi girma ya nuna haɗari mafi girma ga ƙwayar cutar zuciya.
- Ƙarin apoB100: Apolipoprotein B100 na taimakawa wajen sarrafawa , aiwatarwa da kuma sadar da "mummunan cholesterol" zuwa kwayoyin halitta; Ƙaddamar da matakan apoB100 yana taimakawa wajen ƙayyade nau'in da / ko hanyar high cholesterol.
- Lp (a) cholesterol: Binciken ya nuna cewa Lp (a), wanda yayi kama da LDL, wani lamari ne mai hadari ga atherosclerosis.
- IDL: A lipoprotein na matsakaici yawa; a cewar Atherotech, wannan adadin ya karu tsakanin mutane da tarihin iyali na ciwon sukari.
- LDL-RC: LDL wanda ke da alaka da gina jiki C-reactive; irin wannan LDL ana samuwa a shafin yanar gizo na atherosclerotic plaques a cikin jiki, wanda shine daya daga cikin siffofin da ke dauke da cututtuka da kuma - lokacin da suke rushewa - wanda ya fara haifar da kullun zuciya.
- Jimlar Jimlar LDL-C: Jimlar Lp (a), IDL da LDL.
- LDL Girman Tsarin: An yi rahotonsa a matsayin ɗaya daga cikin nau'i uku - A, A / B ko B. A kwaikwayon A, kwayoyin LDL sun fi girma kuma ƙasa mai yawa, yana sa su sauƙi ga jiki don cirewa. A tsarin A / B, akwai haɗin haske da ƙananan kwayoyin. A tsarin B, ƙananan, ƙananan kwayoyin suna rinjaye. A cewar Atherotech, marasa lafiya da kananan ƙwayoyin LDL (B) suna da haɗari na hudu na cutar cututtukan zuciya fiye da marasa lafiya da LDL size pattern A.
- HDL-2: Kayan tsari na "kyakkyawan cholesterol" wanda yake kare lafiyar cututtukan zuciya. Ƙananan lambobi a nan na iya haifar da haɗari na cututtuka na jijiyoyin jini, koda a waɗanda ke da matakan cholesterol na al'ada.
- HDL-3: Wani sashi na HDL, wadda ba ta kare kariya daga cututtukan jini kamar yadda aka yi a matsayin HDL-2.
- VLDL-3: A triglyceride-mai arziki mai lalata lipoprotein; wasu nazarin na nuna yiwuwar daidaita tsakanin lambobin VLDL-3 mafi girma da cigaban ciwon sukari.
Har ila yau, jarrabawar VAP tana ba wa mutane da mafi kyawun yanayin da suke fuskanta ga ciwon da ke ciki , haɗuwa da dalilai da ke da muhimmanci wajen haɓakar haɗari mutum zai ci gaba da ciwon sukari ko cutar cututtukan zuciya.
Ka'idodin manufofi na Cholesterol daga ka'idodi na ADA / ACC 2008 sun hada da manufofin LDL-C, wadanda ba HDL-C da APOB, waɗanda suke cikin VAP amma ba su da wani ɓangare na gwajin cholesterol.
Sources:
Bioletto, Silvana, Alain Golay, Robert Munger, Barbara Kalix da Richard W. James. "Ciwon Hyperinsuline Matu da Ƙananan Ƙananan-Ƙananan da Ƙananan Lafiya Lipoprotein Subfractions a Obese Subjects." Jaridar Amirka na Cibiyar Gina Jiki ta 71 (2000): 443-449.
Crider, Kristin. "Kwararren Lipoprotein Phenotype da Genotype." CDC.gov. 2 Nuwamba 2007. Cibiyoyin Kula da Cututtuka.
"Fact Sheet: A VAP Cholesterol Test." Mafi Mashalar Cholesterol Test - VAP . 2008. Atherotech, Inc.
Kulkarni, KR, DW Garber, SM Marcovina da JP Segrest. "Ma'anar ƙwayar Cholesterol a cikin dukkan ɗakunan Lipoprotein ta hanyar hanyar VAP-II." Journal of Research Lipid. 35 (1994) 159-168.
> Mayo Clinic Staff. "Testing Cholesterol: Yin watsi da Lipids." MayoClinic.com . 1 Feb 2007. Cibiyar Mayo.
"Ciwo mai cututtuka." Ciwon maganin ƙwayar cuta . 2014. Amurka Heart Association.
Singh, SK, MV Suresh, B Voleti da Agrawal. "Haɗin tsakanin Tsarin C-reactive da Atherosclerosis." Annals na Medicine. 40.2. 16 NOV 2007 110-120.
Ziajka, Bulus. "Yin amfani da Testing Lipid da aka ƙaddamar daga VAH daga Atherotech don Tattauna Tsarin Gudanar da Nazarin Jiyya." 2008. Atherotech.